Aligos Therapeutics (AGLS) IPO Opens 17% Higher

Today's IPO for Aligos Therapeutics, Inc. (NASDAQ: ALGS) opened for trading at $17.40 after pricing 10,000,000 shares of its common stock at a public offering price of $15.00 per share.

J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.

In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price.

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

You May Also Be Interested In

• Jersey Mike’s Subs targets up to $1.09 billion raise in US IPO
• 3Knights Dynamics Group files for Nasdaq IPO at $4-$5 per share
• Jaguar Uranium releases preliminary surface samples from Argentina project